Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Stem Cell
Huvudupphovsmän: Choi, Michael Y., Widhopf, George F., Ghia, Emanuela M., Kidwell, Reilly L., Hasan, Md Kamrul, Yu, Jian, Rassenti, Laura Z., Chen, Liguang, Chen, Yun, Pittman, Emily, Pu, Minya, Messer, Karen, Prussak, Charles E., Castro, Januario E., Jamieson, Catriona, Kipps, Thomas J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001723/
https://ncbi.nlm.nih.gov/pubmed/29859176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2018.05.018
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk